4-(((benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid | 150823-40-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-(((benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid
• 英文别名: Z-L-Glu-OMe；Z-Glu-OMe；4-{[(Benzyloxy)carbonyl]amino}-5-methoxy-5-oxopentanoic acid；5-methoxy-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 150823-40-8
• 化学式: C₁₄H₁₇NO₆
• mdl: MFCD01457303
• 分子量: 295.292
• InChiKey: BGMCTGARFXPQML-UHFFFAOYSA-N

物化性质

• 沸点：
  510.6±50.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(((benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.13h， 生成 ethyl N-(N-(4-benzyloxycarbonylamino-4-methoxycarbonylbutanoyl)thiazolidine-4-carbonyl)glycinate
  参考文献：
  名称：

  Synthesis and antitrypanosomal evaluation of some thiazole-containing amino acids and peptides

  摘要：

  Several amino acids and peptides containing thiazole and thiazolidine residues were prepared. They were tested in vivo and in vitro as possible antitrypanosomal compounds. Some derivatives showed a slight activity. As they are structurally related to glutathione, their inhibitory properties towards glutathionylspermidine synthetase, trypanothione synthetase and trypanothione reductase were determined. No inhibitory activity was found.

  DOI：

  10.1016/0223-5234(93)90125-x
• 作为产物：
  描述：

  在 N,N-二甲基丙烯基脲 作用下， 以 二氯甲烷 、 水 为溶剂， 以62 %的产率得到4-(((benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid
  参考文献：
  名称：

  可见光下伯和仲酰胺的选择性水解

  摘要：

  酰胺水解是有机化学中一个根本性的重要转变。在温和条件下开发具有广泛底物范围的水解程序是可取的。在此，通过利用光响应辅助邻硝基苯胺，我们建立了一个温和的两步水解伯和仲酰胺的协议。该协议由室温下中性条件下的可见光照射驱动，可容忍许多酸和碱敏感的官能团。可以选择性地水解各种药物、天然产物和氨基酸衍生的酰胺。

  DOI：

  10.1021/acs.orglett.3c00354

文献信息

• [EN] PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009069100A1

  公开（公告）日：2009-06-04

  The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

  这项发明涉及含有膦酸基团的2-苯基嘧啶衍生物，以及它们作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况中的使用，包括人类和其他哺乳动物中的血栓形成。（I）。
• SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20110046089A1

  公开（公告）日：2011-02-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 4 , R 5 , R a , R b , n, W and Z are as defined in the application, their preparation and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式I化合物的制备及其用途，式中R1、R2、R4、R5、Ra、Rb、n、W和Z的定义如申请中所述，以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关状况的用途，包括人类和其他哺乳动物中的血栓症。
• [EN] SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL-PYRIDINE SUBSTITUÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009125366A1

  公开（公告）日：2009-10-15

  The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式(I)化合物，其中R1、R2、R4、R5、Ra、Rb、n、W和Z如申请中所定义，它们的制备以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关的状况的应用，包括人类和其他哺乳动物中的血栓。
• [EN] THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE THIAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010122504A1

  公开（公告）日：2010-10-28

  The present invention relates to thiazole derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式(I)的噻唑衍生物及其作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关的状况，包括人类和其他哺乳动物中的血栓。
• [EN] CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS<br/>[FR] GLUTARAMIDES CYCLOPENTYLE ET UTILISATION DE CES COMPOSES COMME INHIBITEURS D'ENDOPEPTIDASE NEUTRE (NEP)
  申请人：PFIZER LTD

  公开号：WO2004056787A1

  公开（公告）日：2004-07-08

  The invention relates to NEP inhibitors for treating cardiovascular disorders wherein R1 is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC,-C3alkyl; R2 is hydrogen or C1-C6alkyl; L is an aromatic heterocyclic ring, optionally substituted with C,­ C6alkyl or halo; R3 is C1-C6alkyl optionally substituted by halo, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group, or R3 is phenyl or aromatic heterocyclyl each of which may be independently substituted by one or more alkyl, halo, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group; R4 and R5 are either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen; p is 0, 1 or 2; and q is 1 or 2.

  该发明涉及NEP抑制剂，用于治疗心血管疾病，其中R1为C1-C6烷基，C1-C6烷氧基C1-C3烷基或C1-C6烷氧基C1-C6烷氧基，R2为氢或C1-C6烷基，L为芳香杂环环，可选择性地取代为C，C6烷基或卤素，R3为C1-C6烷基，可选择性地取代为卤素，烷氧基，卤代烷氧基，烷基硫醚，卤代烷基硫醚或腈基，或R3为苯基或芳香杂环基，每个基团可独立地取代为一个或多个烷基，卤素，卤代烷基，烷氧基，卤代烷氧基，烷基硫醚，卤代烷基硫醚或腈基；R4和R5要么都是氢，要么R4和R5中的一个是氢，另一个是在患者体内被氢取代的生物易降解酯基团；p为0、1或2；q为1或2。

表征谱图